Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Lilly in August began sending cease-and-desist letters to telehealth companies, wellness centers and medical spas selling compounded versions of Zepbound and Mounjaro. The company has also filed ...

GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...

It is tailored to patients being treated with Lilly's oncology drugs – which ... than 30 DiGAs that have approved for use by the BfArM medical regulator and are covered by the national GKV ...

Medical industry giants Eli Lilly and Merck will collaborate with Purdue through a new institute, which aims to advance ...

outpacing the Medical sector's loss of 5.64% and lagging the S&P 500's loss of 0.36% in that time. Market participants will be closely following the financial results of Eli Lilly in its upcoming ...

surpassing the Medical sector's loss of 6.22% and falling behind the S&P 500's loss of 1.7%. Investors will be eagerly watching for the performance of Eli Lilly in its upcoming earnings disclosure.